Sunovion Pharmaceuticals Inc. (Sunovion) today announced positive results from GOLDEN-5, a long-term safety study evaluating SUN-101 (glycopyrrolate), a nebulized, long-acting muscarinic antagonist (LAMA) delivered via an innovative investigational nebulizer system (SUN-101/eFlow®). The study results showed that SUN-101/eFlow® was well-tolerated as a twice-daily maintenance treatment for bronchoconstriction in people with moderate-to-very severe chronic obstructive pulmonary disease (COPD), with a similar overall incidence of adverse events to standard of care treatment. Results also showed that the incidence of major adverse cardiovascular events
Developing new treatments for diseases often requires large numbers of clinical research participants enrolled in the same study at numerous geographical sites. These multisite clinical trials are well-positioned to discover whether a promising therapeutic is safe and effective, and may provide medical professionals with the information needed for treating their patients. However, the initiation of such studies may be delayed because each site typically relies on its own Institutional Review Boards (IRBs) to provide ethics reviews of the risks and
IACT Health’s CEO, Jeff Kingsley, discusses the globalization of the clinical trial industry and how IACT is able to provide cost effective, high quality research for pharmaceutical companies all over the world.
Columbus is one of eight sites in the world participating in a groundbreaking study in the war against Type 1 Diabetes. “If you look at it from the perspective our community, I don’t believe there’s ever been a study of this magnitude at this stage of development that is this profound awarded to Columbus, Georgia, “ says Dr. Steven Leichter, Senior Physician at Endocrine Consultants. The study focuses on restorative therapy to keep insulin levels maintained or restored using a
A collaboration between Endocrine Consultants, IACT Health and Columbus Regional Health has brought the TIGER Study to the Columbus area. The medical study investigates the effect of a new drug call golimunab on pediatric patients who have the onset of Type 1 diabetes within 100 days of entry into the study. Columbus is one of eight sites in the world to participate in the study. The announcement was made Wednesday morning at Midtown Medical Center. http://www.ledger-enquirer.com/news/article141442194.html
ABC’s Maureen Akers interviews Dr. Sarah Afework and Dr. Adam Chowdhury to discuss the purpose of clinical trials and how IACT is able to provide healthcare services to participating individuals. Columbus Regional Research Institute is an IACT research facility and those interested can contact a professional either by phone, web request or walk-in.
Women who participated in obstetrics and gynecology clinical trials experienced improved health outcomes compared to those who were not involved in trials, according to research by Queen Mary University of London in England. The researchers found this to be the case regardless of whether or not the trial’s treatment was found to be effective.1 The researchers conducted a review of 21 studies that focused on pregnancy and reproductive health. The review included 20,160 women and found that clinical trial participants